Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses VCEL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VCEL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Dominick Colangelo | $860,000 | $0 | $3,964,630 | $5,456,287 | $860,000 | $0 | $15,451 | $11,156,368 |
| President and Chief Executive Officer | ||||||||
| Michael Halpin | 562,000 | 0 | 1,140,510 | 1,569,617 | 337,200 | 0 | 14,669 | 3,623,996 |
| Chief Operating Officer | ||||||||
| Joe Mara | 525,000 | 0 | 1,004,735 | 1,382,758 | 315,000 | 0 | 14,869 | 3,242,362 |
| Chief Financial Officer | ||||||||
| Jonathan Hopper | 494,000 | 0 | 760,340 | 1,046,411 | 247,000 | 0 | 14,885 | 2,562,636 |
| Chief Medical Officer | ||||||||
| Sean Flynn | 484,000 | 0 | 760,340 | 1,046,411 | 242,000 | 0 | 14,669 | 2,547,420 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Dominick Colangelo | $11,156,368 | $10,237,525 | $7,056,422 | +918,843 |
| Michael Halpin | 3,623,996 | 3,316,286 | 2,382,869 | +307,710 |
| Joe Mara | 3,242,362 | 2,974,002 | 2,147,765 | +268,360 |
| Jonathan Hopper | 2,562,636 | 2,132,047 | 1,578,425 | +430,589 |
| Sean Flynn | 2,547,420 | 2,117,195 | 1,563,273 | +430,225 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Heidi Hagen | Director | 2026-03-23 | A | 15,000 | $3 | $41,400 | Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-03-23 | D | 15,000 | 32 | 486,150 | Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-03-23 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-03-25 | A | 15,000 | 3 | 41,400 | Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-03-25 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-04-02 | A | 3,472 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-04-02 | D | 3,472 | 35 | 121,520 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-04-02 | A | 3,472 | 11 | 38,018 | Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lisa Wright | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Zerbe | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lisa Wright | Director | 2026-04-29 | A | 3,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lisa Wright | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Zerbe | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-04-29 | A | 3,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lisa Wright | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Robert L. Zerbe | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Robert L. Zerbe | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-05-06 | D | 3,433 | 38 | 130,454 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-05-06 | D | 1,422 | 41 | 57,591 | Common | Form 4 ↗ |
| Joe Mara | Chief Financial Officer | 2026-05-07 | D | 5,000 | 41 | 202,500 | Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-05-11 | D | 2,500 | 33 | 82,625 | Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-05-11 | D | 7,500 | 33 | 244,800 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | A | 3,500 | 13 | 45,675 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | A | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | A | 3,500 | 3 | 9,205 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | D | 3,500 | 33 | 114,870 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | D | 3,500 | 33 | 114,905 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | A | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-02 | D | 4,375 | 35 | 153,125 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-02 | A | 4,375 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-02 | A | 4,375 | 17 | 72,888 | Common | Form 4 ↗ |
| Michael Halpin | Chief Operating Officer | 2026-06-18 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Halpin | Chief Operating Officer | 2026-06-18 | D | 10,000 | 40 | 402,400 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-18 | D | 15,000 | 40 | 603,150 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-18 | A | 15,000 | 16 | 243,750 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Halpin | Chief Operating Officer | 2026-06-18 | A | 10,000 | 17 | 166,600 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | A | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | A | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-06-26 | D | 2,500 | 45 | 112,250 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | D | 5,000 | 45 | 225,000 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | D | 5,000 | 45 | 225,000 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-26 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joe Mara | Chief Financial Officer | 2026-06-26 | D | 5,000 | 45 | 223,750 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | A | 5,000 | 30 | 149,100 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-26 | A | 15,000 | 16 | 243,750 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-06-26 | D | 232 | 45 | 10,417 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-06-26 | A | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-06-26 | A | 2,500 | 30 | 74,550 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-26 | D | 15,000 | 46 | 684,600 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | A | 5,000 | 30 | 149,100 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 2,500 | 30 | 74,550 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | D | 2,500 | 49 | 122,250 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 1,500 | 35 | 52,350 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-30 | — | 2,000 | — | — | 1 insider, 2 accrual rows | ||
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | D | 1,500 | 49 | 73,350 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 500 | 30 | 14,910 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | D | 500 | 49 | 24,450 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Heidi Hagen | Director | 2026-03-23 | A | 15,000 | $3 | $41,400 | Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-03-23 | D | 15,000 | 32 | 486,150 | Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-03-23 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-03-25 | A | 15,000 | 3 | 41,400 | Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-03-25 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-04-02 | A | 3,472 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-04-02 | D | 3,472 | 35 | 121,520 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-04-02 | A | 3,472 | 11 | 38,018 | Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lisa Wright | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Zerbe | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan L. Rubino | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lisa Wright | Director | 2026-04-29 | A | 3,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lisa Wright | Director | 2026-04-29 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Zerbe | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-04-29 | A | 3,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heidi Hagen | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lisa Wright | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Robert L. Zerbe | Director | 2026-04-29 | A | 3,200 | — | — | Common | Form 4 ↗ |
| Robert L. Zerbe | Director | 2026-04-29 | A | 3,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-05-06 | D | 3,433 | 38 | 130,454 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-05-06 | D | 1,422 | 41 | 57,591 | Common | Form 4 ↗ |
| Joe Mara | Chief Financial Officer | 2026-05-07 | D | 5,000 | 41 | 202,500 | Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-05-11 | D | 2,500 | 33 | 82,625 | Common | Form 4 ↗ |
| Paul K. Wotton | Director | 2026-05-11 | D | 7,500 | 33 | 244,800 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | A | 3,500 | 13 | 45,675 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | A | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | A | 3,500 | 3 | 9,205 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | D | 3,500 | 33 | 114,870 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | D | 3,500 | 33 | 114,905 | Common | Form 4 ↗ |
| Kevin F. McLaughlin | Director | 2026-05-13 | A | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-02 | D | 4,375 | 35 | 153,125 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-02 | A | 4,375 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-02 | A | 4,375 | 17 | 72,888 | Common | Form 4 ↗ |
| Michael Halpin | Chief Operating Officer | 2026-06-18 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Halpin | Chief Operating Officer | 2026-06-18 | D | 10,000 | 40 | 402,400 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-18 | D | 15,000 | 40 | 603,150 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-18 | A | 15,000 | 16 | 243,750 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Halpin | Chief Operating Officer | 2026-06-18 | A | 10,000 | 17 | 166,600 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | A | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | A | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-06-26 | D | 2,500 | 45 | 112,250 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | D | 5,000 | 45 | 225,000 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | D | 5,000 | 45 | 225,000 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-26 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joe Mara | Chief Financial Officer | 2026-06-26 | D | 5,000 | 45 | 223,750 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | A | 5,000 | 30 | 149,100 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-26 | A | 15,000 | 16 | 243,750 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-06-26 | D | 232 | 45 | 10,417 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-06-26 | A | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-06-26 | A | 2,500 | 30 | 74,550 | Common | Form 4 ↗ |
| Sean Flynn | Chief Legal Officer | 2026-06-26 | D | 15,000 | 46 | 684,600 | Common | Form 4 ↗ |
| Jonathan Hopper | Chief Medical Officer | 2026-06-26 | A | 5,000 | 30 | 149,100 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 2,500 | 30 | 74,550 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | D | 2,500 | 49 | 122,250 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 1,500 | 35 | 52,350 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | D | 1,500 | 49 | 73,350 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 500 | 30 | 14,910 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | D | 500 | 49 | 24,450 | Common | Form 4 ↗ |
| Jonathan Siegal | Principal Accounting Officer | 2026-07-30 | A | 1,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Joe Mara | OPTION | 2025-02-20 | — | — | 46,250 | — | $1,382,758 |
| Dominick Colangelo | RSU | 2025-02-20 | — | — | 73,000 | — | 3,964,630 |
| Michael Halpin | OPTION | 2025-02-20 | — | — | 52,500 | — | 1,569,617 |
| Jonathan Hopper | RSU | 2025-02-20 | — | — | 14,000 | — | 760,340 |
| Jonathan Hopper | OPTION | 2025-02-20 | — | — | 35,000 | — | 1,046,411 |
| Sean Flynn | OPTION | 2025-02-20 | — | — | 35,000 | — | 1,046,411 |
| Michael Halpin | RSU | 2025-02-20 | — | — | 21,000 | — | 1,140,510 |
| Joe Mara | RSU | 2025-02-20 | — | — | 18,500 | — | 1,004,735 |
| Dominick Colangelo | OPTION | 2025-02-20 | — | — | 182,500 | — | 5,456,287 |
| Sean Flynn | RSU | 2025-02-20 | — | — | 14,000 | — | 760,340 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Joe Mara | $1,004,735 | $0 | $1,382,758 | 0.0% |
| Dominick Colangelo | 3,964,630 | 0 | 5,456,287 | 0.0% |
| Michael Halpin | 1,140,510 | 0 | 1,569,617 | 0.0% |
| Jonathan Hopper | 760,340 | 0 | 1,046,411 | 0.0% |
| Sean Flynn | 760,340 | 0 | 1,046,411 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sean Flynn | RSU | 9,000 | — | $324,090 |
| Jonathan Hopper | Option | 28,438 | 54.31 | — |
| Dominick Colangelo | RSU | 73,000 | — | 2,628,730 |
| Dominick Colangelo | RSU | 11,700 | — | 421,317 |
| Joe Mara | RSU | 9,250 | — | 333,093 |
| Dominick Colangelo | Option | 148,282 | 54.31 | — |
| Michael Halpin | RSU | 15,750 | — | 567,158 |
| Michael Halpin | RSU | 10,500 | — | 378,105 |
| Michael Halpin | RSU | 21,000 | — | 756,210 |
| Michael Halpin | Option | 42,657 | 54.31 | — |
| Joe Mara | RSU | 13,875 | — | 499,639 |
| Joe Mara | Option | 14,454 | 29.82 | — |
| Dominick Colangelo | Option | 57,032 | 29.82 | — |
| Dominick Colangelo | Option | 102,657 | 48.31 | — |
| Sean Flynn | Option | 9,375 | 29.82 | — |
| Jonathan Hopper | Option | 9,375 | 29.82 | — |
| Michael Halpin | Option | 5,579 | 34.9 | — |
| Joe Mara | Option | 4,017 | 34.9 | — |
| Sean Flynn | Option | 3,391 | 34.9 | — |
| Joe Mara | Option | 26,016 | 48.31 | — |
| Michael Halpin | Option | 29,532 | 48.31 | — |
| Joe Mara | Option | 37,579 | 54.31 | — |
| Sean Flynn | Option | 16,875 | 48.31 | — |
| Joe Mara | RSU | 2,755 | — | 99,208 |
| Sean Flynn | RSU | 6,000 | — | 216,060 |
| Jonathan Hopper | RSU | 6,000 | — | 216,060 |
| Jonathan Hopper | Option | 3,391 | 34.9 | — |
| Jonathan Hopper | Option | 16,875 | 48.31 | — |
| Dominick Colangelo | RSU | 54,750 | — | 1,971,548 |
| Jonathan Hopper | RSU | 2,325 | — | 83,723 |
| Dominick Colangelo | RSU | 36,500 | — | 1,314,365 |
| Jonathan Hopper | RSU | 14,000 | — | 504,140 |
| Joe Mara | RSU | 18,500 | — | 666,185 |
| Sean Flynn | RSU | 14,000 | — | 504,140 |
| Jonathan Hopper | RSU | 9,000 | — | 324,090 |
| Michael Halpin | RSU | 3,825 | — | 137,738 |
| Sean Flynn | RSU | 2,325 | — | 83,723 |
| Michael Halpin | Option | 16,407 | 29.82 | — |
| Dominick Colangelo | Option | 17,063 | 34.9 | — |
| Sean Flynn | Option | 28,438 | 54.31 | — |
The objectives of our executive compensation program are to attract, retain and motivate talented executives who are critical for the continued growth and success of Vericel and to align the interests of these executives with those of our shareholders. As such, our executive compensation program seeks to focus our leadership team on those key metrics that are critical drivers for executing on the Company's strategy and achieving long-term sustainable growth. We foster a pay-for-performance culture by setting metrics in our incentive compensation plans that reflect our business plan, the operating framework for achieving it and the goals we communicate to investors.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-29 | 36,350,150 | 9,725,057 | 30,539 | 78.89% | Passed |
| 2025 | 2025-04-30 | 40,777,685 | 4,353,149 | 88,363 | 90.35% | Passed |
| 2024 | 2024-05-01 | 41,241,020 | 2,005,128 | 36,561 | 95.36% | Passed |
| 2023 | 2023-05-03 | 38,363,722 | 3,240,444 | 150,314 | 92.21% | Passed |
| 2022 | 2022-04-27 | 34,787,364 | 5,495,748 | 100,481 | 86.36% | Passed |
| 2021 | 2021-04-28 | 35,562,851 | 1,518,522 | 36,611 | 95.9% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-04-29 | 78.89%a |
| 2025 | 2025-04-30 | 90.35%b |
| 2024 | 2024-05-01 | 95.36%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on this Proposal 2.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on this Proposal 2.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on this Proposal 3.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 40 : 1 |
|---|---|
| CEO total compensation | $11,156,368 |
| Median employee compensation | $276,377 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert L. ZerbeIndependent · Board Chair · Audit | $107,500 | $121,664 | $166,136 | $0 | $0 | $395,300 |
| Alan L. RubinoIndependent · Audit · Compensation (Chair) | 77,500 | 121,664 | 166,136 | 0 | 0 | 365,300 |
| Kevin F. McLaughlinIndependent · Audit (Chair) | 70,000 | 121,664 | 166,136 | 0 | 0 | 357,800 |
| Heidi HagenIndependent · Compensation · Governance and Nominating (Chair) | 67,500 | 121,664 | 166,136 | 0 | 0 | 355,300 |
| Paul K. WottonIndependent · Compensation · Governance and Nominating | 60,625 | 121,664 | 166,136 | 0 | 0 | 348,425 |
| Lisa WrightIndependent · Governance and Nominating | 55,000 | 121,664 | 166,136 | 0 | 0 | 342,800 |
| Steven C. GilmanIndependent · Departed during FY | 14,695 | — | — | 0 | 0 | 14,695 |
| Dominick ColangeloEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $287,800 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 10,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $452,820 |
| Equity awards (grant-date value) | $729,984 |
| All other compensation | $0 |
| Total cost of the board | $1,182,804 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Vericel Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Vericel Corp.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 3 | PROCEPT BioRobotics Corporation | 2025 | Larry Wood | 304,830 | 7,217,251 | 7,226,599 | 243,864 | 16,783,853 |
| 4 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 5 | Corcept Therapeutics, Inc. | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 6 | Glaukos Corporation | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 7 | Vericel Corp | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 8 | iRhythm Holdings, Inc. | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 9 | TransMedics Group, Inc. | 2025 | Waleed Hassanein | 776,923 | 4,364,013 | 4,360,147 | 1,400,000 | 10,915,533 |
| 10 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 11 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 12 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 13 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 14 | STAAR Surgical Company | 2025 | Stephen Farrell | 580,000 | 6,836,000 | 0 | 0 | 7,522,385 |
| 15 | Artivion, Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 16 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 17 | Beam Therapeutics, Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 18 | Inari Medical, Inc. | 2023 | Andrew Hykes | 700,000 | 2,606,744 | 937,488 | 826,000 | 5,083,365 |
| 19 | RxSight, Inc. | 2025 | Ron Kurtz | 630,625 | 0 | 3,816,530 | 202,935 | 4,650,661 |
| 20 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Vericel Corp | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia, Inc. |
| Amicus Therapeutics, Inc. | 108% | Options 33 · RSU 33 · PSU 33 | Yes — TSR Goal | Pay Governance |
| Artivion, Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure, Inc. | 141% | PSU 70 · RSU 30 | No | Korn Ferry |
| Beam Therapeutics, Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Corcept Therapeutics, Inc. | 100% | not disclosed | not disclosed | not disclosed |
| Glaukos Corporation | 177.5% | PSU 50 | No | Frederic W. Cook & Co., Inc. |
| Inari Medical, Inc. | 118% | RSU 75 · Options 25 | not disclosed | FW Cook |
| iRhythm Holdings, Inc. | 173% | PSU 50 · RSU 50 | No | Aon (January 1 to May 28) and Mercer (May 29 forward) |
| Ironwood Pharmaceuticals, Inc. | 100% | PSU 50 · RSU 50 | Yes — relative total stockholder return (rTSR) | Alpine Rewards LLC |
| PROCEPT BioRobotics Corporation | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| PTC Therapeutics, Inc. | 167% | Options 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | FW Cook |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance LLC |
| RxSight, Inc. | 32.18% | Options 100 | not disclosed | Aon Human Capital Solutions |
| STAAR Surgical Company | 135% | RSU 50 · PSU 50 | No | Semler Brossy |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon plc (Human Capital Solutions practice) |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
| TransMedics Group, Inc. | 175% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Dominick Colangelo | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Executive Compensation Tables” · page 61. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754 |
| 2 | Section 01, Michael Halpin | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Summary Compensation Table”. As printed: 3,623,996. Filing ↗machine: r7 · c26 · span 643769–643778 |
| 3 | Section 01, Joe Mara | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Summary Compensation Table”. As printed: 3,242,362. Filing ↗machine: r4 · c26 · span 635760–635769 |
| 4 | Section 01, Jonathan Hopper | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Summary Compensation Table”. As printed: 2,562,636. Filing ↗machine: span 659800–659809 |
| 5 | Section 01, Sean Flynn | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Summary Compensation Table”. As printed: 2,547,420. Filing ↗machine: r10 · c26 · span 651768–651777 |
| 6 | Section 03, Joe Mara OPTION | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t262 · r7 · c25 · span 692385–692394 |
| 7 | Section 03, Dominick Colangelo RSU | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t262 · r3 · c25 · span 682301–682310 |
| 8 | Section 03, Michael Halpin OPTION | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t262 · r10 · c25 · span 699908–699917 |
| 9 | Section 03, Jonathan Hopper RSU | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t258 · r13 · c11 · span 658318–658325 |
| 10 | Section 03, Jonathan Hopper OPTION | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t258 · r13 · c15 · span 658681–658690 |
| 11 | Section 03, Sean Flynn OPTION | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t262 · r13 · c25 · span 707425–707434 |
| 12 | Section 03, Michael Halpin RSU | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t262 · r9 · c25 · span 697342–697351 |
| 13 | Section 03, Joe Mara RSU | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t262 · r6 · c25 · span 689819–689828 |
| 14 | Section 03, Dominick Colangelo OPTION | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t262 · r4 · c25 · span 684868–684877 |
| 15 | Section 03, Sean Flynn RSU | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t262 · r12 · c25 · span 704861–704868 |
| 16 | Section 07, pay ratio | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “CEO Pay Ratio”. As printed: 40 : 1. Filing ↗machine: t282 · r1 · c3 · span 876999–877006 |
| 17 | Section 08, Robert L. Zerbe | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Director Compensation”. As printed: 395,300. Filing ↗machine: t198 · r1 · c8 · span 455582–455589 |
| 18 | Section 08, Alan L. Rubino | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Director Compensation”. As printed: 365,300. Filing ↗machine: t198 · r3 · c8 · span 457773–457780 |
| 19 | Section 08, Kevin F. McLaughlin | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Director Compensation”. As printed: 357,800. Filing ↗machine: t198 · r2 · c8 · span 456680–456687 |
| 20 | Section 08, Heidi Hagen | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Director Compensation”. As printed: 355,300. Filing ↗machine: t198 · r4 · c8 · span 458863–458870 |
| 21 | Section 08, Paul K. Wotton | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Director Compensation”. As printed: 348,425. Filing ↗machine: t198 · r5 · c8 · span 459956–459963 |
| 22 | Section 08, Lisa Wright | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Director Compensation”. As printed: 342,800. Filing ↗machine: t198 · r7 · c8 · span 462150–462157 |
| 23 | Section 08, Steven C. Gilman | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Director Compensation”. As printed: 14,695. Filing ↗machine: t198 · r6 · c2 · span 460374–460380 |
| 24 | Section 08, Dominick Colangelo | DEF 14A | 2026-03-19 | 0001308179-26-000094 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 02, Heidi Hagen 2026-03-23 | Form 4 | 2026-03-25 | 0001140361-26-011091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Heidi Hagen 2026-03-23 | Form 4 | 2026-03-25 | 0001140361-26-011091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Heidi Hagen 2026-03-23 | Form 4 | 2026-03-25 | 0001140361-26-011091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Alan L. Rubino 2026-03-25 | Form 4 | 2026-03-27 | 0001140361-26-011730 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Alan L. Rubino 2026-03-25 | Form 4 | 2026-03-27 | 0001140361-26-011730 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Jonathan Hopper 2026-04-02 | Form 4 | 2026-04-06 | 0001140361-26-013334 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Jonathan Hopper 2026-04-02 | Form 4 | 2026-04-06 | 0001140361-26-013334 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Jonathan Hopper 2026-04-02 | Form 4 | 2026-04-06 | 0001140361-26-013334 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Paul K. Wotton 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018542 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Alan L. Rubino 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018540 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Paul K. Wotton 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018542 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Heidi Hagen 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018543 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Kevin F. McLaughlin 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018544 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Alan L. Rubino 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018540 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Alan L. Rubino 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018540 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Lisa Wright 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018539 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Robert L. Zerbe 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018541 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Kevin F. McLaughlin 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018544 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Kevin F. McLaughlin 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018544 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Alan L. Rubino 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018540 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Paul K. Wotton 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018542 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Lisa Wright 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018539 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Lisa Wright 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018539 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Robert L. Zerbe 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018541 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Paul K. Wotton 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018542 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Kevin F. McLaughlin 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018544 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Heidi Hagen 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018543 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Heidi Hagen 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018543 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Heidi Hagen 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018543 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Lisa Wright 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018539 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Robert L. Zerbe 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018541 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Robert L. Zerbe 2026-04-29 | Form 4 | 2026-05-01 | 0001140361-26-018541 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Jonathan Siegal 2026-05-06 | Form 4 | 2026-05-08 | 0001140361-26-020030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Jonathan Siegal 2026-05-06 | Form 4 | 2026-05-08 | 0001140361-26-020030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Joe Mara 2026-05-07 | Form 4 | 2026-05-08 | 0001140361-26-020031 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Paul K. Wotton 2026-05-11 | Form 4 | 2026-05-13 | 0001140361-26-021040 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Paul K. Wotton 2026-05-11 | Form 4 | 2026-05-13 | 0001140361-26-021040 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Kevin F. McLaughlin 2026-05-13 | Form 4 | 2026-05-15 | 0001140361-26-021656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Kevin F. McLaughlin 2026-05-13 | Form 4 | 2026-05-15 | 0001140361-26-021656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Kevin F. McLaughlin 2026-05-13 | Form 4 | 2026-05-15 | 0001140361-26-021656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Kevin F. McLaughlin 2026-05-13 | Form 4 | 2026-05-15 | 0001140361-26-021656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Kevin F. McLaughlin 2026-05-13 | Form 4 | 2026-05-15 | 0001140361-26-021656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Kevin F. McLaughlin 2026-05-13 | Form 4 | 2026-05-15 | 0001140361-26-021656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Jonathan Hopper 2026-06-02 | Form 4 | 2026-06-04 | 0001140361-26-023988 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Jonathan Hopper 2026-06-02 | Form 4 | 2026-06-04 | 0001140361-26-023988 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Jonathan Hopper 2026-06-02 | Form 4 | 2026-06-04 | 0001140361-26-023988 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Michael Halpin 2026-06-18 | Form 4 | 2026-06-22 | 0001140361-26-025952 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Michael Halpin 2026-06-18 | Form 4 | 2026-06-22 | 0001140361-26-025952 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Sean Flynn 2026-06-18 | Form 4 | 2026-06-22 | 0001140361-26-025951 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Sean Flynn 2026-06-18 | Form 4 | 2026-06-22 | 0001140361-26-025951 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Sean Flynn 2026-06-18 | Form 4 | 2026-06-22 | 0001140361-26-025951 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Michael Halpin 2026-06-18 | Form 4 | 2026-06-22 | 0001140361-26-025952 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Jonathan Hopper 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Jonathan Hopper 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Jonathan Siegal 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Jonathan Hopper 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Jonathan Hopper 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Sean Flynn 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026929 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Joe Mara 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Jonathan Hopper 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Sean Flynn 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026929 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Jonathan Siegal 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Jonathan Siegal 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Jonathan Siegal 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Sean Flynn 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026929 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Jonathan Hopper 2026-06-26 | Form 4 | 2026-06-30 | 0001140361-26-026930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Jonathan Siegal 2026-07-30 | Form 4 | 2026-07-31 | 0001140361-26-030487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Jonathan Siegal 2026-07-30 | Form 4 | 2026-07-31 | 0001140361-26-030487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Jonathan Siegal 2026-07-30 | Form 4 | 2026-07-31 | 0001140361-26-030487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Jonathan Siegal 2026-07-30 | Form 4 | 2026-07-31 | 0001140361-26-030487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Jonathan Siegal 2026-07-30 | Form 4 | 2026-07-31 | 0001140361-26-030487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Jonathan Siegal 2026-07-30 | Form 4 | 2026-07-31 | 0001140361-26-030487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Jonathan Siegal 2026-07-30 | Form 4 | 2026-07-31 | 0001140361-26-030487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Jonathan Siegal 2026-07-30 | Form 4 | 2026-07-31 | 0001140361-26-030487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Jonathan Siegal 2026-07-30 | Form 4 | 2026-07-31 | 0001140361-26-030487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 06, 2026 vote | Form 8-K | 2026-05-01 | 0001140361-26-018538 | Item 5.07 · say-on-pay result. As reported: 78.89% (votes for as printed: 36,350,150). Filing ↗ |
| 101 | Section 06, 2025 vote | Form 8-K | 2025-05-02 | 0001140361-25-017110 | Item 5.07 · say-on-pay result. As reported: 90.35% (votes for as printed: 40,777,685). Filing ↗ |
| 102 | Section 06, 2024 vote | Form 8-K | 2024-05-03 | 0001140361-24-024327 | Item 5.07 · say-on-pay result. As reported: 95.36% (votes for as printed: 41,241,020). Filing ↗ |
| 103 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 104 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 105 | Section 09b board cost (computed) | Computed | — | computed | Cash 452,820 + equity 729,984 + all other 0 = 1,182,804, summed across the director compensation table rows.machine: formula: Σ = 1,182,804 |
| 106 | PTC Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410 |
| 107 | Rhythm Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 108 | PROCEPT BioRobotics Corporation, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001588978-26-000017 | CEO total compensation as printed in PROCEPT BioRobotics Corporation's own proxy. As printed: 16,783,853. Filing ↗machine: r2 · c48 · span 520911–520921 |
| 109 | Supernus Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 110 | Corcept Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics, Inc.'s own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 111 | Glaukos Corporation, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-157829 | CEO total compensation as printed in Glaukos Corporation's own proxy. As printed: 12,034,087. Filing ↗machine: t93 · r6 · c38 · span 1876942–1876952 |
| 112 | Vericel Corp (subject), Section 10b CEO total | DEF 14A | 2026-03-19 | 0001308179-26-000094 | CEO total compensation as printed in Vericel Corp's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754 |
| 113 | iRhythm Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001388658-26-000030 | CEO total compensation as printed in iRhythm Holdings, Inc.'s own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508 |
| 114 | TransMedics Group, Inc., Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-150357 | CEO total compensation as printed in TransMedics Group, Inc.'s own proxy. As printed: 10,915,533. Filing ↗machine: r3 · c39 · span 572169–572179 |
| 115 | Alphatec Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191867 | CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158 |
| 116 | AtriCure, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001323885-26-000010 | CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373 |
| 117 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137 |
| 118 | Travere Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 119 | STAAR Surgical Company, Section 10b CEO total | DEF 14A | 2026-05-04 | 0000718937-26-000015 | CEO total compensation as printed in STAAR Surgical Company's own proxy. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486 |
| 120 | Artivion, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001999371-26-007510 | CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882 |
| 121 | Tandem Diabetes Care, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001438133-26-000034 | CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. Filing ↗machine: r3 · c27 · span 866963–866972 |
| 122 | Beam Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161512 | CEO total compensation as printed in Beam Therapeutics, Inc.'s own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178 |
| 123 | Inari Medical, Inc., Section 10b CEO total | DEF 14A | 2024-03-13 | 0001193125-24-066805 | CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517 |
| 124 | RxSight, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187240 | CEO total compensation as printed in RxSight, Inc.'s own proxy. As printed: 4,650,661. Filing ↗machine: t20 · r4 · c24 · span 978530–978539 |
| 125 | Ironwood Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191 |
| 126 | Section 10a, AtriCure, Inc. reciprocity | DEF 14A | — | 0001323885-26-000010 | AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 127 | Section 10a, Tandem Diabetes Care, Inc. reciprocity | DEF 14A | — | 0001438133-26-000034 | Tandem Diabetes Care, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 128 | Section 10a, PTC Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 129 | Section 10a, RxSight, Inc. reciprocity | DEF 14A | — | 0001193125-26-187240 | RxSight, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 130 | Section 10a, Beam Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-161512 | Beam Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 131 | Section 10a, Supernus Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 132 | Section 10a, Travere Therapeutics, Inc. reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics, Inc. names Vericel Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 133 | Section 10a, Inari Medical, Inc. reciprocity | DEF 14A | — | 0001193125-24-066805 | Inari Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 134 | Section 10a, Glaukos Corporation reciprocity | DEF 14A | — | 0001193125-26-157829 | Glaukos Corporation names Vericel Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 135 | Section 10a, Alphatec Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-191867 | Alphatec Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 136 | Section 10a, Rhythm Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals, Inc. names Vericel Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 137 | Section 10a, PROCEPT BioRobotics Corporation reciprocity | DEF 14A | — | 0001588978-26-000017 | PROCEPT BioRobotics Corporation's most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 138 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 139 | Section 10a, Artivion, Inc. reciprocity | DEF 14A | — | 0001999371-26-007510 | Artivion, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 140 | Section 10a, TransMedics Group, Inc. reciprocity | DEF 14A | — | 0001193125-26-150357 | TransMedics Group, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 141 | Section 10a, STAAR Surgical Company reciprocity | DEF 14A | — | 0000718937-26-000015 | STAAR Surgical Company's most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |
| 142 | Section 10a, iRhythm Holdings, Inc. reciprocity | DEF 14A | — | 0001388658-26-000030 | iRhythm Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Vericel Corp. Filing ↗ |